Intended Audience

  • Researchers and healthcare professionals interested in the development, organization, and evolution of large-scale biobanks and genomic cohort studies, including UK Biobank and SG100K.
  • Professionals working on precision medicine research, clinical implementation, and the integration of genomic and healthcare data.
  • Policymakers, business development professionals, and others interested in national genomics strategies, biomedical innovation, and the future of biobanking, including potential implications for Japan.

Executive Summary

  • Singapore's National Precision Medicine Programme (NPM) is a national precision medicine strategy launched in 2017. Its central initiative, PRECISE-SG100K, integrates whole-genome sequences, lifestyle information, physical measurements, and clinical data from approximately 100,000 individuals, primarily of Chinese, Malay, and Indian ancestry.
  • NPM has evolved through three phases: Phase I established a genomic reference resource involving approximately 10,000 individuals; Phase II developed the 100,000-person SG100K cohort; and Phase III, officially launched in November 2025, aims to expand the initiative to more than 500,000 individuals. SG100K reached its recruitment target in April 2025 and completed whole-genome sequencing in June 2025.
  • While UK Biobank has primarily developed as a large-scale research resource, NPM was designed from the outset as an integrated national strategy combining genomic research, implementation within the healthcare system, and biomedical industry development.
  • Its major challenges include improving access to and utilization of research data, establishing the cost-effectiveness of genomic medicine, developing healthcare workforce capabilities and IT systems, safeguarding privacy and public trust, ensuring population representativeness, and achieving sustainable implementation at scale.
  • Although SG100K has achieved a major milestone in data generation, translating those data into a substantial body of research findings and measurable improvements in population health remains a work in progress. The advancement of Phase III between approximately 2027 and 2031 will provide important opportunities to evaluate its success.

1. What Are Singapore's NPM and SG100K?

Singapore's National Precision Medicine Programme (NPM) is a national precision medicine strategy launched in 2017.

At its core is PRECISE-SG100K, a large-scale research infrastructure integrating whole-genome sequences, lifestyle information, physical measurements, and clinical data from approximately 100,000 individuals, primarily from Singapore's Chinese, Malay, and Indian populations.

The initiative resembles the United Kingdom's UK Biobank as a population-based longitudinal research resource. However, there is an important distinction.

While UK Biobank has developed primarily around the creation and provision of a large-scale research resource, NPM was designed from the beginning as an integrated national strategy encompassing genomic research, implementation within the healthcare system, and biomedical industry development.

Its evolution can be understood through three phases.[1][2]

Phase Period Target Population Objectives and Major Activities
Phase I Approximately 2017–2020 Approximately 10,000 Proof of Concept: Established SG10K_Health, a genomic reference resource for Asian populations.
Phase II 2020–2025 Approximately 100,000 Proof of Value: Developed SG100K, linked genomic data with healthcare information, and conducted clinical implementation pilots in five areas.
Phase III 2025–2031 More than 500,000 Proof of Scale: Aims to expand through SG500K/SG-INSIGHT and integrate genomic medicine into routine hospital care.

The start dates of these phases may differ depending on whether a source refers to the beginning of a strategy, the implementation of research activities, or an official announcement. The timeline above primarily follows descriptions provided by Singapore's Ministry of Health.

1.1 Progress as of November 2026

As of the research reference date of November 4, 2026, the main milestones of SG100K and NPM were as follows.[2][3][4]

Item Progress or Scale Date or Additional Information
SG100K participant recruitment Target of 100,000 achieved April 2025
SG100K whole-genome sequencing Completed for 100,000 participants June 2025
Phase III target population More than 500,000 Targeted for approximately 2031
Research data access Restricted, approval-based access Broader access for domestic researchers planned from 2027

It is important to distinguish completed recruitment and sequencing milestones from future Phase III targets.

Whole-genome sequencing of more than 500,000 individuals has not yet been completed.

The current situation can be summarized as follows:

  • Achievements: Establishment of a large-scale, multi-ethnic Asian genomic research resource involving approximately 100,000 individuals, together with institutional and research structures supporting clinical implementation.
  • Ongoing activities: Expansion of genomic applications across healthcare institutions and broader researcher access to genomic and health data.
  • Remaining challenges: Cost-effectiveness in routine clinical practice, healthcare workforce and IT readiness, privacy and public trust, and efficient utilization of research resources.

A particularly important observation is that although SG100K has successfully completed its major data collection objectives, the process of converting these resources into a substantial volume of research findings and sustainable healthcare services remains at a relatively early stage.

In a May 2026 parliamentary response, Singapore's Ministry of Health reported 40 approved applications for access to PRECISE-SG100K and HELIOS data through TRUST, with one publication reported at that time.

However, this figure does not represent the total research output of the entire NPM programme.[5]

2. Why Was NPM Conceived?

Three major factors contributed to the establishment of NPM: scientific needs, healthcare policy priorities, and industrial development objectives.

2.1 The Underrepresentation of Asian Populations in Genomic Research

The first motivation was the insufficient representation of Asian populations in existing large-scale genomic research.

Advances in human genomics were creating opportunities to predict disease risks, estimate drug responses, and identify underlying disease mechanisms using genomic information.

However, many earlier large-scale studies, including UK Biobank, were dominated by participants of European ancestry.

Consequently, polygenic risk scores (PRS) developed using European-ancestry populations and interpretations of pathogenic genetic variants could not necessarily be applied directly to Asian populations with comparable accuracy.

Singapore has a distinctive advantage in this context.

Its population includes substantial Chinese, Malay, and Indian communities, providing opportunities to study genetic diversity associated with East Asian, Southeast Asian, and South Asian ancestry within a relatively small country.

A national strategy paper published in Nature Genetics in 2023 identifies the need to address the underrepresentation of Asian populations in genomic research as one of NPM's central motivations.[1]

2.2 Population Aging and the Increasing Burden of Chronic Diseases

The second motivation was population aging and the growing healthcare burden associated with chronic diseases.

Singapore's government aimed to shift healthcare from a predominantly treatment-oriented model toward one emphasizing disease prediction, early detection, and prevention.

Reducing the burden of diabetes, cardiovascular diseases, cancer, and other major conditions, while controlling rising healthcare expenditure, was an important policy objective.

In a November 2025 speech, Singapore's Minister for Health explicitly identified population aging and increasing healthcare costs as major drivers behind the NPM strategy.[2]

2.3 Developing the Biomedical Industry as a National Growth Sector

The third motivation was the development of the biomedical industry.

Singapore had already established a substantial concentration of research institutions, universities, and international pharmaceutical companies, supported by organizations such as A*STAR.

NPM sought to strengthen this ecosystem further by encouraging innovation in genomic sequencing, diagnostics, drug discovery, healthcare AI, and digital health.

SG100K was therefore conceived not simply as a large-scale cohort study, but as a foundation intended to support three interconnected national policy objectives.

Policy Area Objective
Research Establish genomic reference resources for Asian populations and identify genetic contributors to disease.
Healthcare Enable preventive and personalized healthcare using genomic information.
Industry Promote research, development, and industrial growth in drug discovery, diagnostics, healthcare AI, and related technologies.

NPM provides a national framework for pursuing these objectives together.[1][2]

3. Evolution from 2017 to the Present

NPM began with a scientific and technical demonstration involving approximately 10,000 individuals.

It then expanded into a 100,000-person genomic research infrastructure and subsequently entered a phase focused on large-scale implementation within the healthcare system.

3.1 Timeline of Major Developments

Period Major Development Significance
2017 NPM strategy initiated under RIE2020 Established precision medicine as a national strategic priority.
2017–2019 Phase I: SG10K_Health Sequenced approximately 10,000 genomes and developed multi-ethnic Asian reference data.
2020–2021 Transition to Phase II Prepared for expansion to a 100,000-person research programme.
April 2021 Establishment of PRECISE and official Phase II announcement Created a coordinating organization for research, clinical implementation, and industry collaboration.
Around 2022 Large-scale development of SG100K accelerated Integrated four existing cohorts and recruited additional participants.
2023–2024 Initial data access and clinical implementation pilots Began transitioning from data generation toward research utilization and clinical applications.
August 2024 Approximately 90,000 participants enrolled Demonstrated substantial progress toward the recruitment target.
April 2025 SG100K reached 100,000 participants Completed the major recruitment objective.
June 2025 Whole-genome sequencing completed for 100,000 participants Achieved a principal data generation milestone of Phase II.
November 14, 2025 Official launch of Phase III Announced the SG500K initiative and collaboration among three healthcare clusters.
2026 Expansion of data access, approved research, and clinical implementation studies Continued efforts to increase research utilization and clinical adoption.
From 2027 (planned) Broader data access for domestic researchers Intended to increase utilization of the research infrastructure.
Approximately 2031 (target) Completion of Phase III Aims to establish a genomic healthcare infrastructure covering more than 500,000 individuals.

This timeline draws on announcements from PRECISE, policy statements from Singapore's Ministry of Health, the launch of Phase III, and official data access policies.[2][3][4]

3.2 Phase I: SG10K_Health (Approximately 2017–2020)

The initial phase did not attempt to recruit 100,000 participants immediately.

Instead, it focused on whole-genome sequencing of approximately 10,000 individuals.

A central objective was to characterize the distribution of genetic variants across Singapore's major ethnic populations and establish reference data appropriate for Asian populations.

According to a government announcement in 2021, the construction of genomic data for approximately 10,000 individuals had been completed by October 2019.

Phase I served several purposes.

In addition to demonstrating the technical feasibility of large-scale sequencing, it established a foundation for interpreting genetic variants and generated knowledge needed for the subsequent expansion to a 100,000-person programme.[1]

3.3 Phase II: PRECISE-SG100K (2020–2025)

In April 2021, Singapore's government formally announced the next phase of NPM and established PRECISE as its central coordinating organization.

The official plans at that time included genomic research involving 100,000 healthy individuals, studies involving up to 50,000 patients with specific diseases, clinical implementation demonstrations, and industry development.

It is important to distinguish the proposed patient studies involving up to 50,000 individuals from the subsequent Phase III plan to recruit an additional 400,000–450,000 people.

SG100K adopted a strategy of integrating existing large-scale cohorts maintained by universities and hospitals rather than rebuilding the entire research infrastructure from scratch.

According to an explanation from the National University of Singapore, the original design envisaged combining approximately 70,000 individuals from existing cohorts with approximately 30,000 newly recruited participants.

This approach offered advantages not only in recruitment efficiency but also in the ability to use health information already collected through earlier studies.[1][3]

3.4 Phase III: SG500K/SG-INSIGHT (2025–2031)

Phase III was officially launched on November 14, 2025.

This marked an important shift in the programme's objectives.

While Phase II primarily examined relationships between genomic information and health characteristics in the general population, Phase III places greater emphasis on patients receiving care in healthcare institutions and on incorporating genomic information into clinical decision-making.

The programme aims to recruit approximately 400,000–450,000 additional individuals, increasing the total population covered to more than 500,000.

This corresponds to approximately 10% of Singapore's resident population.

Three major healthcare groups are participating:

  • NHG Health
  • National University Health System (NUHS)
  • SingHealth

Phase III also introduced the concept of SOAR (Sequence Once, Analyse Repeatedly).

Under this model, a person's entire genome would be sequenced once and reanalyzed repeatedly throughout their lifetime as new clinical needs arise.

However, the general applicability and cost-effectiveness of this model remain subjects for evaluation during Phase III.[2][4]

4. Key Characteristics of SG100K as a Research Infrastructure

SG100K is more than a programme for collecting large volumes of whole-genome sequencing data.

Its distinctive characteristics include a multi-ethnic study population, integration of existing research cohorts, extensive phenotypic information, and linkage with national healthcare data infrastructure.

4.1 Emphasis on Chinese, Malay, and Indian Populations

One of SG100K's most important characteristics is its inclusion of multiple Asian ancestry groups to complement genomic research that has historically been dominated by European-ancestry populations.

The original recruitment plan aimed for the following approximate ethnic composition.

Population Group Original Target Proportion
Chinese 60%
Malay 20%
Indian 20%

These proportions were not intended simply to reproduce Singapore's overall population composition.

Instead, they represented a research design intended to ensure sufficient representation of minority populations for meaningful analysis.

This enables comparisons of disease risks, drug responses, and interactions between genetic and environmental factors across different populations.

However, the three groups cannot be assumed to represent all Asian populations.

Genetic and socioeconomic diversity within each group must also be considered.[1]

4.2 Integration of Four Existing Cohort Studies

SG100K was developed by integrating several existing research cohorts.

The four principal contributing cohorts were:

Cohort Main Institution Research Characteristics
HELIOS Nanyang Technological University (NTU) Population health research involving detailed measurements of lifestyle, physical function, and molecular characteristics.
SPHS National University of Singapore (NUS) Population health and epidemiological research involving multiple ethnic groups.
SEED Singapore Eye Research Institute (SERI) Research on eye diseases, retinal imaging, and their relationships with systemic diseases.
SingHeart National Heart Centre Singapore (NHCS) Research focused on cardiovascular health.

These cohorts were integrated to form PRECISE-SG100K as a large-scale shared resource for genomic research.[1][3]

An important advantage of this strategy was the ability to reuse existing participants, survey data, and research infrastructure.

At the same time, the integration of different cohorts created structural challenges related to harmonizing data elements, measurement protocols, and study conditions.

4.3 Extensive Phenotypic Data Beyond Genomics

SG100K is not limited to whole-genome sequencing.

It combines genomic information with lifestyle characteristics, physical measurements, medical imaging, socioeconomic and psychological information, and clinical records.

Data Domain Main Data Types
Genomics Short-read whole-genome sequencing for approximately 100,000 individuals, with approximately 30× coverage
Lifestyle Diet, physical activity, smoking, medication use, medical history, and related information
Physical measurements Height, weight, body composition, blood pressure, and related measurements
Cardiovascular health Electrocardiograms and arterial or vascular assessments
Respiratory function and activity Lung function testing and accelerometer-based physical activity measurements
Imaging DXA measurements of bone density and body composition, carotid ultrasound, fundus photography, OCT, and related imaging
Socioeconomic and psychological information Socioeconomic status, mental health, cognitive function, and related characteristics
Healthcare data Linkage with electronic medical records, diagnoses, laboratory tests, treatments, and related clinical information

Some imaging and detailed examination data are available only for subsets of participants.

Therefore, not every data element is available for all 100,000 individuals.

Additional molecular layers, including multi-omics data, are also intended to be expanded progressively.[3][4]

4.4 Linkage with the National Healthcare Data Platform, TRUST

Another important feature is the linkage of research data with electronic healthcare information generated during routine clinical care.

TRUST is a national platform supporting the secure sharing and analysis of health research and real-world clinical data.

Integrated SG100K data are made available to approved researchers through this infrastructure.

The relationship among the main data sources and research applications can be summarized as follows.

Data Source or Platform Content and Role
SG100K Genomic data, biospecimens, lifestyle information, and phenotypic measurements
Healthcare information Diagnoses, laboratory tests, treatments, clinical outcomes, and related records
TRUST Secure data linkage and analytical environments for anonymized research data
Research applications Disease research, risk prediction models, and investigation of disease mechanisms
Clinical implementation research Evaluation of clinical effectiveness and cost-effectiveness

UK Biobank also supports linkage with healthcare records.

However, NPM is distinctive in treating the translation of research findings into the national healthcare system as an explicit objective of the overall programme.[3][5]

5. How Is Genomic Research Being Translated into Healthcare?

During Phase II, five Clinical Implementation Pilots (CIPs) were conducted.

These pilots were designed to examine how genomic information could be incorporated into real-world clinical practice.

5.1 Five Clinical Implementation Pilots

Clinical Area Main Implementation Activities
Breast cancer Risk-stratified breast cancer screening using PRS and related information
Hereditary cancer Improving access to genetic testing and promoting testing among family members
Familial hypercholesterolemia (FH) Genetic diagnosis and cascade screening among relatives
Primary glomerular diseases Early genetic diagnosis of conditions such as Alport syndrome
Pharmacogenomics (PGx) Preemptive genetic testing to reduce adverse drug reactions

According to a paper published in npj Genomic Medicine in July 2026, more than 6,000 patients and their family members underwent clinical genetic testing through the five pilots.[6]

5.2 Familial Hypercholesterolemia as an Implementation Example

Familial hypercholesterolemia (FH) is a representative example of efforts to translate genomic research into healthcare services.

A 2026 clinical implementation paper reported improvements to an algorithm using electronic medical records to identify patients who might benefit from genetic testing.

Initially, 2,890 individuals were identified based on elevated LDL cholesterol levels.

By incorporating additional information, including family history, the number of candidates recommended for testing was reduced to 589.

Screening Stage Number of Candidate Patients
Initial identification based on elevated LDL cholesterol 2,890
After refinement using family history and other information 589

This illustrates a strategy aimed not simply at increasing the volume of genetic testing, but at identifying appropriate patients efficiently and optimizing the use of healthcare resources.

Health economics specialists also participated in the implementation pilots to evaluate testing costs, clinical workflows, workforce requirements, and patient outcomes.[6]

6. Six Major Challenges Facing NPM and SG100K

Based on official announcements and academic publications available in 2026, the major challenges facing NPM and SG100K can be grouped into six categories.

6.1 Challenge 1: Research Data Utilization Has Not Yet Fully Matured

Although SG100K has completed whole-genome sequencing for approximately 100,000 individuals, research access to the data is still being expanded progressively.

According to the official data access policy updated in October 2026, a total of 65 projects had been approved through research calls conducted in 2024 and 2026.

Broader access for public-sector and clinical researchers based in Singapore is planned from 2027.

Meanwhile, a parliamentary response issued by Singapore's Ministry of Health in May 2026 reported 40 approved applications for access to PRECISE-SG100K and HELIOS data through TRUST.

Of these, 34 involved public-sector researchers and six involved private companies.

At that time, one publication had been reported from these approved applications.

Indicator Number or Status
Approved TRUST-based applications as of May 2026 40
Public-sector researcher applications 34
Private-sector applications 6
Publications reported at that time 1
Approved projects reported in the October 2026 policy update 65 in total
Broader data access for domestic researchers Planned from 2027

The figures of 40 and 65 cannot be compared directly because they refer to different reporting dates and definitions of approval.

Similarly, the figure of one publication does not represent the total research output of NPM.

Nevertheless, these figures suggest that external research utilization and the accumulation of resulting outputs remain at a relatively early stage compared with the scale of data generation.[3][5]

The key challenge is to develop SG100K into a research infrastructure used continuously by a large community of researchers, as UK Biobank has done.

This will require improvements in access procedures, the speed of data provision, analytical environments, publication of research results, and opportunities for data reuse.

6.2 Challenge 2: The Cost-Effectiveness of Genomic Medicine Remains Uncertain

Although the cost of whole-genome sequencing has declined, implementation in healthcare involves many expenses beyond sequencing itself.

These include:

  • Genetic variant analysis
  • Clinical interpretation
  • Genetic counseling
  • Testing of family members
  • Healthcare information system development
  • Long-term management of genomic results

NPM is evaluating whether genomic medicine can improve health outcomes and reduce healthcare expenditure or workforce burdens compared with conventional approaches.

The 2026 clinical implementation study identifies financial constraints, workforce capacity, and digital health policy as important barriers to large-scale implementation.[6]

A key distinction is that demonstrating the usefulness of genetic testing for specific diseases does not necessarily establish that population-wide whole-genome sequencing is cost-effective.

The two questions require different forms of evidence.

6.3 Challenge 3: Healthcare Workforce and Clinical Workflow Limitations

Using genomic information in routine healthcare requires professionals who can accurately interpret genetic testing results.

Singapore has been developing education and training for physicians, nurses, and research coordinators, together with new professional roles supporting genetic counseling.

Another challenge is the structure of primary care.

Approximately 80% of primary care is provided by private healthcare institutions, where information systems and operational procedures are not necessarily standardized.

Consequently, extending genetic testing and clinical implementation models developed in hospitals to family physicians and community clinics presents challenges involving data integration, clinical workload, and decision-support systems.[6]

Genomic information is highly identifiable and can contain information relevant not only to individuals but also to their biological relatives.

NPM envisages storing genomic information over long periods, linking it with healthcare records, and potentially reanalyzing it as new clinical needs emerge.

This creates several important questions:

  • How should consent be managed for future research uses that could not be anticipated when data were collected?
  • Under what conditions should genomic and health data be shared between public-sector researchers and private companies?
  • How can genetic discrimination and other potential disadvantages be prevented?
  • How can the scientific value of genomic data be maximized while protecting individual privacy?

PRECISE uses an approval-based access model.

Participation by overseas researchers and companies is subject to additional requirements, including Singapore-led research collaboration and demonstrable benefits to Singapore.

These arrangements are intended to protect public trust and national interests.

However, they also require balancing these objectives against the flexibility needed for international research collaboration.[1][3]

6.5 Challenge 5: Population Representativeness and Generalizability

The multi-ethnic composition of SG100K is a major strength.

However, it does not necessarily mean that the cohort represents all Asian populations.

Additional validation would be required before applying risk prediction models developed from SG100K to populations such as Japanese, Korean, Vietnamese, Thai, or diverse Indonesian groups.

There is also the issue of selection bias.

When individuals voluntarily participate in research, they may differ from the general population in health awareness, educational attainment, income, previous medical conditions, and other characteristics.

A study of the HELIOS cohort, which contributes to SG100K, published in December 2025 found that participants had a higher proportion of women, lower smoking prevalence, and more years of education than the national average.

The key challenge is therefore not only to ensure genetic diversity, but also to evaluate socioeconomic diversity and equity in healthcare access.

6.6 Challenge 6: Scalability During Expansion to SG500K

Phase III aims to expand the population covered by genomic research and healthcare applications to more than 500,000 individuals, with greater emphasis on patients receiving clinical care.

This is not simply an increase in the amount of data.

It introduces challenges across the boundary between research and routine healthcare, including:

  • Clinical-grade genomic analysis
  • Data quality assurance
  • Long-term storage
  • Reanalysis of genomic findings
  • Interoperability with healthcare information systems
  • Communication of results to patients
  • Clinical follow-up based on genomic findings

If AI-based patient identification and clinical decision support are expanded, additional questions will arise regarding algorithmic bias, excessive alerts, transparency, auditability, and responsibility for clinical decisions.[2][6]

7. Comparison with UK Biobank

A comparison with UK Biobank is useful for understanding the distinctive position of Singapore's NPM and SG100K.

Both initiatives involve large-scale population-based genomic and health research infrastructure.

However, their approaches differ in research resource management, clinical implementation, and their relationships with national industrial policy.

7.1 Comparison of Key Characteristics

Dimension UK Biobank Singapore NPM/SG100K
Basic positioning Large-scale population-based longitudinal research resource National precision medicine strategy and large-scale research infrastructure
Beginning Recruited approximately 500,000 participants between 2006 and 2010 NPM began in 2017; SG100K expanded substantially during Phase II
Research population Approximately 500,000 Approximately 100,000 in SG100K; more than 500,000 targeted in Phase III
Ethnic composition Predominantly participants of European ancestry Emphasis on Chinese, Malay, and Indian populations
Genomic data Whole-genome sequencing for approximately 500,000 participants Whole-genome sequencing completed for approximately 100,000 participants during Phase II
Phenotypic data Lifestyle, physical measurements, laboratory tests, imaging, and related information Lifestyle, physical measurements, imaging, laboratory tests, and related information
Longitudinal follow-up Linkage with healthcare records and repeat assessments Linkage with healthcare records and long-term follow-up
Researcher access Broad approval-based access for international researchers Phased approval-based access, with an emphasis on domestic researchers
Clinical implementation Primarily contributes to healthcare through resulting research findings Clinical implementation is an explicit core component of the national programme
Industrial policy Research resource is also available to companies Domestic biomedical industry development is an explicit policy objective

This comparison is based on UK Biobank research information, the NPM national strategy paper, and official Singaporean programme materials.[1][2][3]

A research project directly comparing UK Biobank and SG100K was also registered with UK Biobank in February 2026.

The project aims to investigate ethnic and environmental differences in biomarkers and disease risk prediction across the two cohorts.

However, this represents a registered research plan rather than established research findings.

7.2 Difference 1: The Timeline of Research Infrastructure Development and Clinical Implementation

UK Biobank has expanded and enriched its research resources over many years while supporting research outputs from external investigators.

NPM has developed healthcare economic evaluation and clinical implementation mechanisms alongside the creation of its genomic research infrastructure.

This difference is important when comparing the development strategies of the two initiatives.

7.3 Difference 2: International Accessibility of Research Data

Providing data to researchers around the world is a central function of UK Biobank.

In contrast, SG100K prioritizes domestic research and places additional conditions on international collaborations.

These differences may influence future publication output, participation by external researchers, and the use of genomic data by pharmaceutical companies.

7.4 Difference 3: Integration with the National Healthcare System

NPM coordinates policy objectives, research infrastructure, healthcare institutions, data platforms, and industrial development at a national level.

This creates opportunities to test how large-scale genomic data can be directly incorporated into healthcare policy and routine clinical practice.

In this respect, its approach differs from that of UK Biobank.

Although the two initiatives share similarities as large-scale research infrastructures, they play different roles within their respective national strategies.

8. Future Directions and Key Evaluation Indicators

Over the coming years, NPM should be evaluated not only by the number of genomes sequenced, but also by the outcomes it produces.

8.1 How Should Research, Healthcare, and Social Outcomes Be Evaluated?

Evaluation Area Key Indicators
Research utilization Number of approved data access applications, time required to begin data use, publications, research collaborations
Scientific outcomes Findings specific to Asian populations, improvements in PRS accuracy, discovery of new disease-associated factors
Clinical effectiveness Earlier disease detection, more appropriate treatment selection, reduction in adverse drug reactions
Health economics Quality-adjusted life years (QALYs), incremental cost-effectiveness ratios, total healthcare expenditure, healthcare resource utilization
Equity Differences in testing rates and health outcomes across ethnic and socioeconomic groups
Public trust Participant retention, renewed consent, understanding and acceptance of data sharing
Sustainability Data storage and reanalysis costs, workforce capacity, integration into routine healthcare systems

These indicators have been organized based on the objectives and challenges described in NPM materials.

They should not all be interpreted as formally adopted programme KPIs.

8.2 Issues to Watch During Phase III

Phase III aims to establish a large-scale genomic healthcare infrastructure covering more than 500,000 individuals.

Its success will depend not only on the number of people sequenced, but also on whether genomic information can be incorporated effectively into routine healthcare.

Four issues deserve particular attention:

  • The SOAR model: Can sequencing a genome once and reanalyzing it throughout life work effectively in routine clinical settings?
  • Clinical effectiveness: Does genomic information lead to earlier disease detection, more appropriate treatment selection, fewer adverse drug reactions, and measurable improvements in health?
  • Cost-effectiveness and sustainability: Can genomic medicine demonstrate economic value and become a sustainable component of the healthcare system?
  • Equity: Can genomic medicine be implemented without increasing disparities in healthcare access and health outcomes across ethnic and socioeconomic groups?

These will be important questions to evaluate as Phase III advances between approximately 2027 and 2031.[2][6]

9. Overall Assessment and Implications for Japan

9.1 What SG100K Has Achieved

SG100K reached a major milestone in 2025 by establishing a large-scale genomic cohort focused on Asian populations.

In 2026, a paper reviewing Singapore's national precision medicine strategy was published in Nature Genetics, followed by a paper reviewing its clinical implementation efforts in npj Genomic Medicine.

Together, these publications provide a clearer picture of how Singapore is connecting national strategy, genomic research infrastructure, and clinical implementation.[6][7]

However, completing a research resource is different from generating a substantial and sustained body of research findings.

It is also different from achieving measurable improvements in population health.

9.2 Two Transitions That Will Determine Future Success

Two transitions will be particularly important for NPM's future success.

The first is whether SG100K can evolve from a predominantly domestic data resource into a research infrastructure that continuously generates a substantial volume of scientific findings.

Completing data collection is a major achievement, but it does not, by itself, establish the long-term success of a research infrastructure.

Expanding access for external researchers and supporting the continued generation of high-quality research outcomes will be essential.

The second is whether Phase III can demonstrate that genomic information provides clinical and economic value and can be implemented sustainably within the healthcare system.

There are significant technical and institutional challenges between sequencing genomes and using the resulting information to improve patient health.

Phase III represents an effort to address these challenges at the national level.

9.3 Implications for Japan's Genomics and Biobanking Strategies

Singapore's experience offers important lessons when considering large-scale genomic research infrastructures such as UK Biobank.

Four elements are particularly relevant to the future development of genomics and biobanking strategies in Japan.

Integration of existing research cohorts

Rather than building every component of a new research infrastructure from the beginning, existing cohorts and research resources can be brought together within a shared framework.

Development of a national data linkage infrastructure

Genomic information, lifestyle data, laboratory results, and clinical records can be integrated to support research and healthcare applications.

Incorporation of health economic evaluation into implementation studies

Evaluations should examine not only scientific or clinical effectiveness, but also cost-effectiveness and practical feasibility in healthcare settings.

Collaboration with healthcare institutions across the country

Research institutions and healthcare providers can collaborate from the outset with the intention of translating research findings into routine clinical practice.

These elements may be valuable when considering how genomic research resources can be developed and utilized within Japan's healthcare and research systems.

9.4 Conclusion

Singapore's NPM and SG100K have evolved from an initiative resembling an "Asian UK Biobank" into a national programme designed to test how genomic information can be used in real-world healthcare.

Its most distinctive characteristic is the integration of large-scale genomic and health data infrastructure with clinical implementation and biomedical industry development as part of a coordinated national strategy.

Nevertheless, successfully collecting genomic data is only one step.

Significant challenges remain in turning these data into research findings and clinical benefits, including data accessibility, cost-effectiveness, workforce capacity, privacy, population representativeness, and sustainable implementation.

The period from approximately 2027 to 2031, when Phase III is expected to advance substantially, will provide particularly important opportunities to assess the programme's outcomes.

NPM and SG100K therefore represent initiatives worth following not only for their contributions to large-scale genomic research, but also for what they may reveal about translating genomic research infrastructure into meaningful benefits for healthcare and society.

References

The following academic publications and official materials from the Singapore government and PRECISE form the principal sources for this article.

[1] “The Singapore National Precision Medicine Strategy,” Nature Genetics, 2023.
https://www.nature.com/articles/s41588-022-01274-x

[2] Singapore Ministry of Health, “Speech by Mr Ong Ye Kung, Minister for Health and Coordinating Minister for Social Policies, at the Launch of NPM Programme Phase III,” November 14, 2025.
https://www.moh.gov.sg/newsroom/speech-by-mr-ong-ye-kung--minister-for-health-and-coordinating-minister-for-social-policies--at-the-launch-of-npm-programme-phase-iii/

[3] PRECISE, “Data Access to PRECISE-SG100K,” updated October 2026.
https://www.npm.sg/our-data-users/data-access/data-access-to-precise-sg100k/

[4] Singapore Ministry of Health, “National Precision Medicine Programme Phase III,” 2025. Official announcements and policy information on Phase III. See also Reference [2].

[5] Singapore Ministry of Health, “Data on Approved Access Applications to PRECISE, SG10K and HELIOS, Research Productivity and Outcomes, and Plans for Public Registry,” May 7, 2026.
https://www.moh.gov.sg/newsroom/data-on-approved-access-applications-to-precise--sg10k-and-helios--research-productivity-and-outcomes--and-plans-for-public-registry/

[6] “Building a Precision Health Ecosystem: Singapore’s Approach to Innovation through the Clinical Implementation Pilots,” npj Genomic Medicine, July 28, 2026.
https://www.nature.com/articles/s41525-026-00594-9

[7] “Translating genomic data into healthcare practice with the Singapore National Precision Medicine program,” Nature Genetics, July 29, 2026.
https://www.nature.com/articles/s41588-026-02687-8

Research Reference Date

This article is based on information available as of November 4, 2026, drawing on official materials from the Singapore government and PRECISE, together with academic publications.

Figures relating to participant recruitment, completion of whole-genome sequencing, approved research applications, and scientific publications refer to the specific reporting dates of their respective sources.

The Phase III target of more than 500,000 individuals, its anticipated completion around 2031, and the planned expansion of data access from 2027 are objectives and plans announced as of the reference date, rather than milestones already achieved.